hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06383663 id: 308-2019-04-01 briefTitle: A RCT of Supraclavicular Lymph Node Dissection vs. No-dissection in Supraclavicular Lymph Node Metastatic Breast Cancer overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2028-12-31 date: 2029-12-31 date: 2024-04-25 date: 2024-04-25 name: Sun Yat-sen University class: OTHER briefSummary: The purpose of this study was to compare the efficacy of surgical dissection of supraclavicular lymph nodes combined with radiotherapy versus radiotherapy alone in patients with ipsilateral supraclavicular lymph node metastasis. conditions: Breast Cancer conditions: Ipsilateral Supraclavicular Lymph Node Metastasis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Supraclavicular lymph node dissection combined with radiotherapy versus radiotherapy alone primaryPurpose: TREATMENT masking: NONE count: 452 type: ESTIMATED name: Supraclavicular lymph node dissection combined with radiotherapy name: radiotherapy measure: DFS measure: PFS measure: OS measure: pCR rate sex: FEMALE minimumAge: 35 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06383650 id: 124532 briefTitle: Use of 81 vs 325mg of ASA in Treatment of BCVI overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-05 date: 2025-09 date: 2024-04-25 date: 2024-04-25 name: London Health Sciences Centre class: OTHER name: Western University briefSummary: Blunt cerebrovascular injury (BCVI), or injury to the carotid and vertebral arteries, occurs in 1-3% of blunt traumas, often as a result of injury to the head, neck, or chest. If unrecognized or untreated, BCVI can lead to stroke, which occurs in approximately 20% of untreated patients, potentially causing significant and sometimes permanent disability. Early diagnosis and treatment significantly reduce the risk of stroke.
Currently, there is wide variation across centers and trauma care providers in treatment strategies for BCVI and the most recent guidelines are unable to make specific recommendations about the optimal agent and/or dose of treatment to reduce the risk of stroke after BCVI while minimizing bleeding complications in patients with multiple traumatic injuries. Recent systematic reviews and meta-analyses evaluating the most common treatment strategies for BCVI have shown similar stroke rates with the use of anticoagulants (usually heparin) vs. antiplatelets (usually aspirin/ASA), however, treatment with antiplatelets was associated with a lower risk of bleeding complications. The optimal dose of ASA for stroke prevention while minimizing bleeding complications is unknown, and more research is required to inform future care.
This project will investigate two doses of antiplatelet therapy (81 mg daily vs. 325 mg daily aspirin) for BCVI treatment, and will look at the risk of stroke and bleeding complications with each strategy. The goal of the research is to determine whether a large-scale study looking at this question is feasible, which will ultimately help determine the best medical therapy for patients with BCVI. conditions: Carotid Artery Injuries conditions: Traumatic Injury conditions: Vertebral Artery Injury studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: Acetylsalicylic Acid measure: Study feasibility measure: Incidence of stroke measure: Incidence of Bleeding Complications sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06383637 id: KAP-ABR-Interns briefTitle: Antibiotic Use and Resistance KAP Among Dental Interns overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2024-11-01 date: 2024-12-01 date: 2024-04-25 date: 2024-04-25 name: Cairo University class: OTHER briefSummary: The study is designed as a cross-sectional online-based questionnaire, and it will be distributed among dental interns. Assess the following among dental interns (1) The knowledge, attitude, and practices (KAP) towards antibiotics and antibiotic resistance; (2) The correlation between their KAP score and where they spend their internship year? (4) Development of the curriculum to provide sufficient training and information about antibiotics and antibiotic resistance. conditions: Antibiotic Side Effect conditions: Antibiotic Resistant Infection studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 343 type: ESTIMATED measure: Knowledge of dental interns regarding antibiotic use and resistance sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06383624 id: RC18-4-2023 briefTitle: Impact Of Maternal Spinal Anesthesia-Induced Hypotension At Scheduled Cesarean Delivery On Risk Development Of Transient Tachypnea Of Newborn And Fetal Acidosis overallStatus: COMPLETED date: 2023-04-01 date: 2024-03-01 date: 2024-03-31 date: 2024-04-25 date: 2024-04-25 name: Benha University class: OTHER briefSummary: We will evaluate the association between transient tachypnea of newborns and fetal acidosis development to the degree and duration of maternal hypotension and anesthesia to delivery time during spinal anesthesia at scheduled cesarean delivery. conditions: Transient Tachypnea of Newborn and Fetal Acidosis studyType: OBSERVATIONAL observationalModel: CASE_CROSSOVER timePerspective: PROSPECTIVE count: 115 type: ACTUAL measure: Association between transient tachypnea of newborns development to the degree and duration of maternal hypotension during spinal anesthesia at scheduled cesarean delivery measure: Association between fetal acidosis development to the degree and duration of maternal hypotension and anesthesia to delivery time during spinal anesthesia at scheduled cesarean delivery sex: ALL minimumAge: 1 Minute maximumAge: 6 Hours stdAges: CHILD facility: Benha University Hospital city: Cairo zip: 13511 country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06383611 id: OTX-0303 briefTitle: Expanded Access to Cyclic Irrigation in Patients Undergoing Exchange Arthroplasty acronym: APEX-EAP overallStatus: AVAILABLE date: 2024-04-25 date: 2024-04-25 name: Osteal Therapeutics, Inc. class: INDUSTRY briefSummary: The objective of the protocol is to provide access to the VT-X7 (Vancomycin, Tobramycin Exchanged in 7 Days) system for subjects with periprosthetic joint infection (PJI) of the hip or knee who lack therapeutic treatment alternatives. conditions: Prosthetic-joint Infection studyType: EXPANDED_ACCESS name: VT-X7 Treatment System sex: ALL minimumAge: 22 Years maximumAge: 84 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06383598 id: 2022KT74-ZY01 briefTitle: PD-L1 Specific [68Ga]-Nb-1 Nanobody Probe for PET Imaging in Solid Tumors overallStatus: RECRUITING date: 2024-05-09 date: 2026-12 date: 2026-12 date: 2024-04-25 date: 2024-04-25 name: Peking University Cancer Hospital & Institute class: OTHER briefSummary: The objective of the study is to constrcut a noninvasive approach 68Ga-Nb-1 PET/CT to detect the PD-L1 expression of tumor lesions in patients with solid tumors and to identify patients benefiting from anti-PD-L1 treatment. conditions: Solid Tumor studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 50 type: ESTIMATED name: 18F-FDG measure: Standardized uptake value（SUV） sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Cancer Hospital status: RECRUITING city: Beijing state: Beijing zip: 100142 country: China name: Hua Zhu role: CONTACT phone: +861088196495 email: zhuhuananjing@163.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06383585 id: 24-001367 briefTitle: 3D DL Ozteo in the Detection of Osseous Changes in Patients With Inflammatory Arthritis overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2026-06 date: 2026-12 date: 2024-04-25 date: 2024-04-25 name: Mayo Clinic class: OTHER name: GE Healthcare briefSummary: This project intends to explore and validate the utility of new MRI pulse sequence, 3D DL oZTEo, in the detection of osseous erosions of the hand in patients with inflammatory arthritis. The detection of osseous structural changes, such as erosive disease, is routinely assessed in patients with rheumatic conditions such as rheumatoid arthritis, as it alters clinical management, and in some cases assists in diagnosis. Currently, this is most often assessed with radiography and conventional MRI. conditions: Inflammatory Arthritis studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 25 type: ESTIMATED name: oZTEo measure: The binary (yes/no) presence of bony erosions as detected by hand MRI with and without the addition of the 3D DL oZTEo sequence. measure: The number of erosions (continuous) as detected by hand MRI with and without the addition of the 3D DL oZTEo sequence. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic in Rochester city: Rochester state: Minnesota zip: 55905 country: United States lat: 44.02163 lon: -92.4699 hasResults: False
nctId: NCT06383572 id: 2024-0196 id: NCI-2024-03505 type: OTHER domain: NCI-CTRP Clinical Registry briefTitle: Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies overallStatus: NOT_YET_RECRUITING date: 2024-10-31 date: 2027-04-01 date: 2029-04-01 date: 2024-04-25 date: 2024-04-25 name: M.D. Anderson Cancer Center class: OTHER briefSummary: To find a recommended dose of PRAME-TCR-NK cells that can be given to patients with AML or MDS. conditions: Lymphodepleting Chemotherapy conditions: Myeloid Malignancies studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 54 type: ESTIMATED name: Cyclophosphamide name: Fludarabine phosphate name: Decitabine measure: Safety and adverse events (AEs) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: MD Anderson Cancer Center city: Houston state: Texas zip: 77030 country: United States name: Jeremy Ramdial, MD role: CONTACT phone: 713-745-0146 email: jlramdial@mdanderson.org name: Jeremy Ramdial, MD role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06383559 id: TJMUCH-GI-GC07 briefTitle: Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients overallStatus: RECRUITING date: 2023-12-01 date: 2026-07-01 date: 2026-09-01 date: 2024-04-25 date: 2024-04-25 name: Tianjin Medical University Cancer Institute and Hospital class: OTHER briefSummary: This is a multi-center, prospective, open label phase 2 study evaluating the safety and efficacy of standard first-line chemotherapy XELOX regimen combined with Sintilimab (anti-PD-1 antibody) and Lenvatinib in the treatment of advanced AFP-positive gastric cancer. This study was conducted in the Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Institute and Hospital. Previous phase 1 dose escalation study (TJMUCH-GI-GC002) has demonstrated that such combinational pattern was well tolerated with promising efficacy. In this study, patients with AFP-positive and HER-2-negative advanced gastric cancer who had not received palliative systematic treatment in the past will be enrolled. Patients who met the inclusion criteria were treated with XELOX regimen combined with Sintilimab plus Lenvatinib every 3 weeks until disease progression or intolerable adverse reactions or death. The treatment regimen is XELOX chemotherapy (oxaliplatin 130mg/ m2, d1, capecitabine 850-1250 mg/m2, bid, d1-14, every 3 weeks) in combination with Sintilimab (\>=60kg, 200 mg; \<60kg, 3mg/kg; intravenous infusion, every 3 weeks) plus Lenvatinib (determined from previous phase 1 study, 16mg, orally once a day). Patients received regular and periodic reviews, with imaging evaluations every 6 weeks. Safety will be evaluated by AE and laboratory tests. conditions: Gastric Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 39 type: ESTIMATED name: Lenvatinib and Sintilimab measure: ORR measure: OS measure: PFS measure: AE sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tianjin Medical University Cancer Institute and Hospital status: RECRUITING city: Tianjin state: Tianjin country: China name: Ting Deng, MD role: CONTACT phone: 022-23340123 phoneExt: 1053 email: xymcdengting@126.com name: Yi Ba, MD role: CONTACT phone: 022-23340123 phoneExt: 1053 email: bayi@tjmuch.com lat: 39.14222 lon: 117.17667 hasResults: False
nctId: NCT06383546 id: XHEC-C-2024-053-1 briefTitle: Artificial Intelligence-enabled ECG Detection of Congenital Heart Disease in Children: a Novel Diagnostic Tool acronym: AI-ECG-CHD overallStatus: RECRUITING date: 2024-01-01 date: 2024-12-30 date: 2025-12-30 date: 2024-04-25 date: 2024-04-25 name: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine class: OTHER briefSummary: Congenital heart disease (CHD) is the most common congenital disease in children. The early detection, diagnosis and treatment of CHD in children is of great significance to improve the prognosis and reduce the mortality of children, but the current screening methods have limitations. Electrocardiogram (ECG), as an economical and rapid means of heart disease detection, has a very important value in the auxiliary diagnosis of CHD.Big data and deep learning technologies in artificial intelligence (AI) have shown great potential in the medical field. The advent of the big data era provides rich data resources for the in-depth study of CHD ECG signals in children. The development of deep learning technology, especially the breakthrough in the field of image recognition, provides a strong technical support for the intelligent analysis of electrocardiogram. The particularity of children electrocardiogram requires the development of a special algorithm model. At present, the research on the application of deep learning models to identify children's electrocardiograms is limited, and the training and verification from large data sets are lacking. Based on the Chinese Congenital Heart Disease Collaborative Research Network, this project aims to integrate data and deep learning technology to develop a set of intelligent electrocardiogram assisted diagnosis system (CHD-ECG AI system) suitable for children with CHD, so as to improve the early detection rate of CHD and improve the efficiency of congenital heart disease screening. conditions: Artificial Intelligence conditions: Electrocardiogram conditions: Deep Learning conditions: Congenital Heart Disease in Children conditions: Diagnosis studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 30000 type: ESTIMATED measure: Large-scale ECG database for children measure: Artificial intelligence-assisted electrocardiogram model for CHD in Children sex: ALL minimumAge: 3 Months maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine status: RECRUITING city: Shanghai state: Shanghai country: China name: Sun Jing, MD role: CONTACT phone: 15618497517 email: sunjing02@xinhuamed.com.cn lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06383533 id: IRB-2023-385 briefTitle: Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma overallStatus: RECRUITING date: 2023-05-01 date: 2025-05-01 date: 2025-12-31 date: 2024-04-25 date: 2024-04-26 name: Zhejiang Cancer Hospital class: OTHER briefSummary: It is a single arm, open-label, phase II cinical trial to evaluate the efficacy and safety of Disitamab Vedotin Plus Cadonilimab in second-line treatment of patients with Advanced or Metastatic Bile Duct Adenocarcinoma conditions: Bile Duct Adenocarcinoma Non-Resectable conditions: HER2 Gene Mutation studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 28 type: ESTIMATED name: Disitamab Vedotin Plus Cadonilimab measure: Objective response rate(ORR) measure: Overall survival (OS) measure: Progression-free survival (PFS) measure: Disease control rate (DCR) measure: Incidence of Treatment-Emergent 3/4 Adverse Events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Zhejiang Cancer Hospital status: RECRUITING city: Hangzhou state: Zhejiang zip: 310022 country: China name: Jieer Ying, Doctor role: CONTACT phone: 13858195803 email: hzyingjieer@163.com lat: 30.29365 lon: 120.16142 hasResults: False
nctId: NCT06383520 id: XLan-0415 briefTitle: Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma overallStatus: RECRUITING date: 2023-09-30 date: 2024-12-30 date: 2025-12 date: 2024-04-25 date: 2024-04-25 name: Wuhan Union Hospital, China class: OTHER briefSummary: This is a diagnostic study. Patients were recruited from patients with clinically suspected or confirmed hepatocellular carcinoma and healthy volunteers were recruited for PET/or PET/CT imaging targeting a GPC3-specific probe (in the case of 68Ga-NOTA-aGPC3-scFv) , to observe the reaction of volunteers and patients after injection of drugs, to evaluate the pharmacokinetics in vivo and the efficacy of diagnosis and staging, and to perform PET CT imaging in patients with contraindications. General Information, clinical data, blood routine, liver and renal function, and other imaging data were collected. The final diagnosis was based on the histopathology of biopsy or surgical specimens. conditions: Malignant Neoplasm of Liver studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 100 type: ESTIMATED name: 68Ga-aGPC3-scFv/Fab measure: Visual and standardized uptake values assessment of lesions and biodistribution measure: Radioactivity in the blood and urine samples measure: Concentration of tumor markers (e.g., APF) in participants' blood measure: Pathological sections of tumour tissue sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: China, Hubei Province status: RECRUITING city: Wuhan state: Hubei zip: 430022 country: China name: Xiaoli Lan, PhD role: CONTACT phone: +86-027-83692633 email: lxl730724@hotmail.com lat: 30.58333 lon: 114.26667 hasResults: False
nctId: NCT06383507 id: CHT101 briefTitle: A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors overallStatus: NOT_YET_RECRUITING date: 2024-04-22 date: 2027-04-21 date: 2029-04-21 date: 2024-04-25 date: 2024-04-25 name: Zhejiang University class: OTHER briefSummary: This is a single-center, single-arm ，open-label ，dose escalation and dose extension study. In this study we plan to evaluate the safety and efficacy of CD70-targeting UCAR-T cells in the treatment of CD70-positive refractory or relapsed solid tumors, and obtain recommended doses and infusion patterns. conditions: Metastatic Tumor conditions: Advanced Solid Tumor conditions: Renal Cell Carcinoma conditions: Ovarian Cancer conditions: Cervix Cancer conditions: Head and Neck Squamous Cell Carcinoma conditions: Nasopharyngeal Carcinoma studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 18 type: ESTIMATED name: CHT101 measure: Incidence of Adverse events after CD70 UCAR-T cells infusion (Safety and Tolerability) measure: Disease control rate (DCR) measure: Objective response rate (ORR) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06383494 id: IRB-2024-356（IIT） briefTitle: GMA-TulipTM, i-gelTM and the LMA-SupremeTM (LMA-S) Devices in Airway Management overallStatus: RECRUITING date: 2024-04-30 date: 2025-12-30 date: 2025-12-30 date: 2024-04-25 date: 2024-04-26 name: Zhejiang Cancer Hospital class: OTHER briefSummary: Patients were randomly assigned to three extraglottic airway (EGA) devices groups for airway management after anesthesia induced. Fiberoptic bronchoscope (FB) guided glottic exposure grading was performed and other airway management quality was recorded. conditions: Anesthesia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: FACTORIAL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 276 type: ESTIMATED name: LMA supreme group name: I-gel group name: GMA-Tulip measure: Glottic exposure grading measure: Peak inspiratory pressures measure: Pharyngalgia measure: Bleeding sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Zhejiang Cancer Hospital status: RECRUITING city: Hangzhou state: Zhejiang zip: 310022 country: China name: Jiangling Wang, Ph. D role: CONTACT phone: +86 571 88122106 email: wangjl@zjcc.org.cn lat: 30.29365 lon: 120.16142 hasResults: False
nctId: NCT06383481 id: TDK-2024-13362 briefTitle: The Effect of Mobile-Based Education on Postoperative Recovery and Quality of Life in Thyroidectomy Patients overallStatus: NOT_YET_RECRUITING date: 2024-04-22 date: 2025-04-22 date: 2025-08-22 date: 2024-04-25 date: 2024-04-26 name: Ataturk University class: OTHER briefSummary: Thyroid diseases constitute one of the most common health problems around the world and in our country. In its treatment; Drug therapy, radioactive iodine therapy and surgical treatment can be applied alone or together. Advances in the diagnosis of thyroid diseases have led to an increase in the number of thyroidectomies. When there are no complications after thyroidectomy, patients are discharged from the hospital on the day of surgery or are hospitalized for only a few days. In this context, since technical care is given priority, discharge training remains incomplete.
In this study, a mobile application that covers the entire perioperative process and includes education will be developed for patients undergoing thyroidectomy. This developed mobile application aims to manage post-operative problems such as neck pain and discomfort and voice changes experienced by patients, and to improve post-operative recovery, voice quality and, accordingly, quality of life. In this context, it is believed that even in cases where patients cannot access health care professionals, their educational needs will be met, problem management will be provided with applications for the problems they experience, and accordingly, their post-operative recovery, voice and quality of life will increase, starting from the hospital before the surgery until the end of the recovery period, including the home care process after discharge.When the literature on the subject is examined, studies involving education in patients with thyroidectomy are limited. However, no studies have been found on mobile health applications that include training to reduce neck pain and discomfort experienced by thyroidectomy patients, ensure postoperative recovery, and improve voice quality and quality of life. conditions: Thyroid Diseases conditions: Healthy Lifestyle conditions: Thyroid studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 92 type: ESTIMATED name: Mobile based education measure: Postoperative Recovery Index (ASII) measure: SF-36 Quality of Life Scale measure: Visual Comparison Pain Scale(GKAÖ) measure: Turkish- Computer System Usability Questionnaire Short Version (TCSUQ- SV) measure: Neck Pain and Discomfort Scale (BARÖ) measure: Voice Handicap Index (Voice Handicap Index 10)(VHI10) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False